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Objectives: The prevalence of nosocomial infections is between 5-15%. Reduction 
of nosocomial infections, recognition in time and adequate treatment are all empha-
sised activities of patient security. The aim of this examination is to measure theo-
retical and practical knowledge of hand hygiene of nursing students in secondary 
education. MethOds: Cross-sectional qualitative and quantitative was made, with 
non-random, accidental samples in 2014 January with the participation of stu-
dents in secondary nursing education (N= 116) to whom the rules of sepsis, asepsis 
and antisepsis, and correct hand hygiene knowledge were taught according to the 
number of lessons in the curriculum. Self-made opened and closed questionnaires 
were applied, with a focus on the knowledge of hand hygiene. The technique and 
efficiency of hygienic hand disinfection was measured with an infrared lamp. χ 2-
test, t-test, ANOVA were performed as a statistical method besides 95% probability 
(p< 0.05). Data analysis was performed with SPSS 20.0 programs. Results: The con-
cept of disinfection was known correctly by 78% of the students, the exact terminol-
ogy of nosocomial infection was known by 44%. Only 42 students thought that hands 
have the highest relevance in the transfer if infections. The preconditions of proper 
hand hygiene were indicated correctly by 11%. Examination with infrared lamp 
showed that 4 students implemented hand disinfection perfectly. The most common 
missed areas were: the back of the hand, phalanges, nails, thumb. cOnclusiOns: 
Significant reduction of nosocomial infections may and must be reached, to which 
accurate theoretical and practical education of the students is required, and the 
acquirement has to be monitored continuously and strictly.
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Objectives: To identify and understand the importance of reasons mothers of 
young children would choose to vaccinate their child (ren) against rotavirus and the 
impact of vaccine features on vaccine choice and uptake. MethOds: Women with 
children 5 years of age or younger participated in a focus group and semi-structured 
interview to: (1) identify reasons they would choose to vaccinate their children 
against rotavirus independent of the clinical features or cost of the vaccine and (2) 
identify the clinical vaccine features that would influence their decision to vaccinate 
their children. A survey instrument was developed to elicit the relative importance 
of the reasons for vaccination. The survey also included a discrete-choice experi-
ment (DCE) to elicit parents’ preferences for clinical features of hypothetical vac-
cines and likely uptake of vaccines with different clinical features and cost. The 
survey instrument was used in 15 in-depth, face-to-face interviews and the findings 
were used to refine the list of reasons and the clinical vaccine features. Results: 
Study participants identified 7 reasons influencing vaccination decisions – work 
disruptions, child-care disruptions, unplanned expenses, disruptions to routine, 
concern about child’s discomfort, concern about child’s health in the future, concern 
about spreading illness – and 6 clinical vaccine features influencing vaccine choice 
and uptake – number of illnesses prevented, severity of the illnesses prevented, 
duration of illnesses prevented by vaccine, location of vaccination (home or health 
care location), mode of administration (oral or injection), and age at which protec-
tion begins. Cost was also a relevant attribute in these decisions. The reasons for 
vaccination vary with the severity of illness. cOnclusiOns: Deciding to vaccinate 
a child against rotavirus is the result of a decision process that is influenced by 
both the impact of rotavirus on the family, the severity of illness, and the clinical 
characteristics of the vaccine itself.
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Objectives: To identify a parsimonious factor structure for the 43-item PROQOL-
HIV questionnaire as an easy-to-use instrument for measuring health-related 
quality of life in clinical studies. MethOds: Using a representative sample of 
3,022 HIV-infected patients from the Vespa2 French national survey, HRQL was 
summarized using the 8-dimension PROQOL-HIV questionnaire. Exploratory Factor 
Analysis (FA) was used to isolate 4 correlated factors. Dimensionality and internal 
consistency were checked using parallel analysis and Cronbach’s alpha. A con-
firmatory FA was applied on the international validation sample (N= 791, 8 coun-
tries). Summated scale scores were compared to individual scores computed from 
FA and partial credit models. Results: The four dimensions down to: physical 
health and symptoms (11 items, α = 0.931), health concerns and mental distress (10 
items, α = 0.908), social and intimate relationships (7 items, α = 0.898), and treatment 
impact (10 items, α = 0.936). Four items exhibited PROMAX rotated loadings < 0.4, 
three of which were found to cross-load on two factors. This four-factor solution 
suggests acceptable fit to the international validation sample (RMSEA= 0.082, 90% 
CI [0.079; 0.084]; NNFI= 0.880). Correlations between unweighted sum scale scores 
and factor or IRT scores were above 0.9 in most cases. cOnclusiOns: PROQOL-
HIV is the only specific scale taking into account patient’s experience with treat-
ment. This simplified scoring version will allow researchers and clinicians to better 
room visits and hospital admissions. Logistic regressions were constructed to esti-
mate the predictors for resource utilization, and a two-part multivariable analysis 
model was used to determine the total costs of treatment in the UK. Results: Data 
on 731 patients receiving SMV with pegylated interferon and ribavirin (PegIFN/R) 
or PegIFN/R alone were included in the analysis. While MRU was similar between 
SMV and PegIFN/R groups, MRU-related costs were significantly lower in the SMV 
group, compared to the PegIFN/R group (P< 0.05). High body mass index (P< 0.05), 
severe fibrosis (P< 0.05), shortened treatment duration from 48 to 24 weeks (P< 0.05), 
anaemia and rash during treatment (P< 0.001) were identified as predictors of hos-
pitalisation and outpatient visits and as drivers of total costs. Univariate sensitivity 
analyses demonstrated that shortened treatment duration and lower occurrence of 
rash lead to large cost savings. cOnclusiOns: This study identified both baseline 
and on-treatment antiviral therapy characteristics as drivers of MRU-related costs 
for HCV patients following antiviral therapy. The shortened treatment duration and 
reduction in adverse events due to simeprevir treatment lead to extra cost savings 
compared with PegIFN/R treatment. This suggests that there are potential patient 
management and cost-effectiveness implications associated with the choice of 
specific antiviral treatments.
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Objectives: Willingness-to-pay (WTP) to avoid morbidity is a widely-used meas-
ure of disease valuation. This paper aims to meta-analyze variation in mean-WTP 
of avoiding morbidity due to malaria. Benefits from avoiding incidences can be 
approximated for use in cost-benefit analyses (CBA). This study is an improve-
ment over an earlier meta-analysis: Double-counting is avoided (exclusion of same 
study results), new studies and explanatory variables are added (e. g. malaria 
incidence rates). More sophisticated regression techniques are employed to 
deal with issues, such as heteroscedasticity (e. g. multiple observations from a 
single study). Furthermore, other mosquito-borne diseases (filariasis, trypano-
somiasis and encephalitis) are included to test between-disease valuation dif-
ferences. MethOds: A systematic literature review was conducted, resulting in 
a database of 61 studies, yielding 200 data points. A meta-regression model was 
estimated. Dependent variable is mean-WTP per treatment per year in 2012 USD 
(Purchasing Power Parity and inflation adjusted). The explanatory variables con-
sists of (i) treatment characteristics (service, private/public goods etc.), (ii) meth-
odological characteristics (revealed vs. stated preference, WTP elicitation method, 
etc.), and (iii) sample characteristics (age, gender, exposure etc.). Results: 
Standardized mean-WTP range is 0.3 USD and 9000 USD. Data is censored: over 
70% of mean-WTP includes zero-values. Preliminary comparisons show that valu-
ation of malaria avoidance is influenced positively for altruistic interventions and 
negatively for rural samples. The latter is correlated with income- underlining the 
vulnerability of poorer people (due to higher exposure). Additionally, we find sig-
nificantly higher WTP to avoid filariasis over malaria. The meta-regression model 
explains over 30 percent of observed variation between WTP values. Predictive 
power is tested using a jackknife resampling procedure. cOnclusiOns: The 
preliminary results provide policy-makers important information on benefits to 
malaria interventions, with a special focus on rural areas. From a methodological 
perspective, meta-regression helps to improve the practice of benefit transfer, and 
generate improved predictions for CBA.
INfeCtIoN – Patient-reported outcomes & Patient Preference studies
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Objectives: To assess and compare the compliance with anti-HBV antiviral oral 
drugs. MethOds: A pharmaco-epidemiological study, based on the IMS LifeLinkTM 
Treatment Dynamics (LTD) database was used to investigate the frequency and 
the regularity of patients’ deliveries on retail pharmacies for 18 months follow-up 
period between June 2012 and November 2013. Incident patients with no anti-
HBV drug deliveries within the last 3 months were included in the cohort. For the 
follow-up period, patients with no anti-HBV deliveries in a retail pharmacy within 
3 consecutive months were considered having stopped their treatment which can 
lead to an overestimation due to the double dispensing system of these drugs 
in France. Study investigated patients’ demographic characteristics, persistence 
rates, medication possession ratio (MPR) and proportion of days covered (PDC) 
according to initial molecule. Results: 793 patients (median age 50 years old) 
initiated a treatment against HBV (patient with both anti-HBV and HIV treatments 
were excluded); for the follow-up period, 5% of patients switched HBV treatment; 
32% of patients stopped their treatment for the follow-up period. Patients who 
continued their treatment are compliant as MPR is respectively of 160% and 103% 
at 6 and 12 months while PDC values are 82% and 78%. No differences stood out 
among the different treatments, especially between Tenofovir and Entecavir (the 
two often prescribed HBV drugs). Moreover older patients tend to be more compli-
ant than the youngest one. cOnclusiOns: By using the IMS Lifelink longitudinal 
database this study highlights the fact that one third of patients treated with anti-
HBV treatment stopped it within 18 months while these drugs are well tolerated. 
Therefore physicians’ challenge consists consequently in motivating patients to 
continue their treatment even they feel asymptomatic.
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challenges. Self-administered questionnaires were used and data were analyzed 
with SPSS version 16. Results: The mean age was 16.9 ± SD 2.5 and 21 (62%) were 
mainly females and in school. Four were in primary school, 14 in junior secondary 
school, 12 in senior secondary and another 4 in tertiary institutions. Most (85%) 
were aware that young people their age could fall sick, 91% had heard of HIV, 70% 
knew someone with HIV and 45 % thought that adolescents were not at risk of HIV. 
Eighteen (52.9%) knew their HIV status, 17 (50%) were on antiretroviral and 32% of 
these admitted to missing Anti-Retroviral (ARVs) dose. cOnclusiOns: Disclosure 
of HIV status to adolescents and young people is dependent on a complex mix of 
factors and most practitioners recommend an age and developmentally appropriate 
disclosure. The knowledge and awareness of HIV was 91%. There is also the need to 
support care givers to disclose HIV status and to support young people to adhere to 
ARVs for better outcomes. KeywORds: Knowledge; Disclosure Adolescents/Young 
Adults; HIV, Ghana.
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Objectives: The health care system of Ukraine is being transformed according to 
the modern world format. More and more doctors are aware of the need for the use 
of technologies based on evidence-based medicine, particularly in the management 
of hepatitis C. MethOds: In 2013 the multidisciplinary working group involving 
professionals and patients developed an adapted clinical guideline, based on HTAs 
and strategies of evidence-based medicine on the treatment of hepatitis C, and uni-
fied clinical protocol “Viral hepatitis C”. Results: The differences in the treatment 
of hepatitis C in Ukraine compared to the best international practice were revealed 
and considered while developing medical and technological documents for health 
care in hepatitis C. Doctors and the public were informed of modern evidence-based 
technologies concerning management of the hepatitis C. As a result, the multidis-
ciplinary working group adapted these documents of best methodological quality. 
Introduction of these documents reorients doctors on a modern approach to the 
assessment of scientific medical information. The unified clinical protocol contains 
provisions for minimum acceptable quality of primary and specialized medical care 
and the algorithms of patient’s identification. cOnclusiOns: Provision of changes 
in the current medical practice is associated with the introduction of modern medi-
cal technologies based on evidence-based medicine. Ukraine has implemented the 
algorithm for the use of best practice: a multidisciplinary working group adapts 
clinical guidelines based on evidence → creates unified clinical protocols → each 
health institution develops local protocols, taking into account the resources of a 
health facility and interaction of these institutions.
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Objectives: The prevalence of the hepatitis C virus (HCV) remains high amongst 
people who inject drugs (PWID) and accounts for the majority of newly acquired infec-
tions. This study aims to quantify the value of treatment amongst PWID with new 
direct acting antivirals (DAAs) at increased uptake rates, with respect to the avoidance 
of future infections and subsequent long-term complications of HCV. MethOds: A 
dynamic HCV transmission and disease progression model was developed, incorpo-
rating acute and chronic infection and their long-term complications (decompensated 
cirrhosis, cancer, liver transplant and mortality), with the potential for reinfection 
following treatment failure. The model was populated with prevalence and therapy 
data from a UK setting. Scenarios of current standard of care (SoC) treatment efficacy 
and uptake were compared to anticipated sustained virologic response (SVR) rates 
of 90–100% and increased uptake over varied horizons. Results: SoC led to modest 
reductions in prevalence; > 5% after 200 years. New treatments achieving 90% SVR 
could reduce prevalence below 5% within 60 years at current uptake rates or within 5 
years if all patients are treated. Amongst 4,240 PWID, chronic HCV infections avoided 
as a result of increasing treatment uptake over the period 2015–2027 ranged from 
20–580 and 34–912 with SoC and 90% SVR rates respectively. The reduction in down-
stream HCV infections due to increasing treatment uptake resulted in an approximate 
discounted gain of 300 life-years (from avoiding reduced life expectancy from HCV 
infection) and a gain of 1,700 QALYs (from avoiding the disutility of HCV infection 
and related complications), with a projected £5.4 million cost saving. cOnclusiOns: 
While improved SVR profiles led to reductions in modelled prevalence, increased 
treatment uptake was the key driver of future infections avoided. Increased treatment 
among PWID, with new more efficacious therapies, could significantly change the 
future dynamics, cost and health burden of HCV-related disease.
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Objectives: Poor adherence to treatment guidelines undermines the goals of 
malaria treatment with implications for worsening malaria burden. This study 
analyzed the diagnostic and prescription practices for uncomplicated malaria at 
two levels of public health facilities in Nigeria, to assess the current state of compli-
ance to policy. MethOds: Retrospective audit of patients’ records for uncompli-
cated malaria was carried out at a primary/secondary and tertiary health facilities. 
Demographics, diagnostic information, medication and cost data were extracted. 
Data from the two facilities were analyzed and compared for similarities and 
monitor and to correlate HRQL improvements in patients undergoing different 
treatment strategies.
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Objectives: In ATTAIN, a Phase III, randomised, head-to-head comparison study 
of simeprevir versus telaprevir, both with peginterferon/ribavirin (PR), in HCV gen-
otype 1-infected prior null or partial PR responders, simeprevir exhibited better 
safety and tolerability. In this analysis, the impact on patient-reported outcomes 
(PRO) was analysed. MethOds: Patients received simeprevir (150mg QD) or tel-
aprevir (750mg TID, 7-9hrs apart) +PR for 12wks followed by PR alone (36wks) in 
a double-blind, double-dummy design. PRO questionnaires, completed at base-
line, throughout treatment and at follow-up, rated fatigue severity (FSS), depres-
sive symptoms (CES-D), work and daily activities impairment (WPAI: Hepatitis-C), 
health-related quality of life (EQ-5D visual analogue scale), and skin symptoms 
(Skindex-16). During simeprevir/telaprevir treatment, between-treatment mean-
value differences were calculated using area-under-the curve to Wk12 (AUC12) for 
all measures except Skindex-16 where maximum (worst) scores during the first 12 
wks were used. Subgroup analyses evaluated the impact of SVR12, age, fibrosis and 
treatment completion. Results: Compared with normative studies, baseline PRO 
scores indicated greater fatigue, depressive symptoms and daily activities impair-
ment. Mean PRO scores in both groups worsened during the first 12 weeks of treat-
ment, remained stable through Week 48 and returned to values close to baseline at 
end of treatment. Clinically relevant between-treatment differences in FSS, CES-D, 
Skindex-16 and EQ-5D scores indicated less impairment with simeprevir than tel-
aprevir. AUC12 between-treatment differences significantly favoured simeprevir 
for FSS (p= 0.003), WPAI Activity Impairment (p= 0.022), and EQ-5D (p< 0.001). Mean 
Skindex-16 maximum total (p= 0.0087) and subscale scores were significantly lower 
for simeprevir. Subgroup analyses showed less impairment with simeprevir versus 
telaprevir on most PRO scores in patients who failed treatment, were > 45 years old 
or had advanced fibrosis. cOnclusiOns: Simeprevir/PR resulted in less fatigue, 
depressive and skin-related symptoms and less impairment in daily activities than 
telaprevir/PR. These findings provide valuable information on the tolerability of 
these regimens from the patient perspective.
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Objectives: The greatest burden of the HIV infection is felt in sub-Saharan Africa. 
Nigeria is rated among the first three largest countries with HIV population. 
Pharmacists play an important role in the care of HIV patients especially by provid-
ing pharmaceutical care. Thus it is imperative to assess the experience and satisfac-
tion of HIV patients with the pharmaceutical services they receive as this will ensure 
that quality care is rendered. The objective of this study was to assess HIV-infected 
patients’ satisfaction with pharmacy services provided in South-Eastern Nigeria’s 
HIV/AIDS clinics. A secondary aim was to repeat the validation process in order to 
confirm the initial validation of PSPS questionnaire. MethOds: The survey was 
conducted in 6 HIV/AIDS clinics in South-Eastern Nigeria. Multi-stage sampling 
technique was used to select the clinics. Re-validation techniques employed include 
factor analysis, reliability test, and construct validity. The level of satisfaction of the 
participants was determined. Variance in satisfaction score among the different 
demographic variables was also assessed. Results: The response rate was 81.85%. 
The Cronbach alpha value was 0.84. The 16 items of PSPS questionnaire resolved 
into 4 factors as established by the initial validation exercise. Re-validation of the 
PSPS Questionnaire’s construct revealed the same result obtained in the original 
validation as items that were related showed convergence while items that were 
not related showed divergence. With the exception of item 12, the average score 
obtained in the survey was high. Most of the average scores ranged from 4 to 5, 
signifying that responses ranged from agree to strongly agree. cOnclusiOns: HIV 
patients were highly satisfied with services rendered by the pharmacists in South-
Eastern HIV clinics in Nigeria and PSPS proved to be a reliable and valid instrument 
for measuring satisfaction of HIV patients with pharmacy services.
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Objectives: In Ghana it is estimated that 1.7% of HIV infections occur in young 
people aged 15-24. Despite this the representation of young people in our clinics is 
small. Adherence to treatment, appointment keeping and knowledge of HIV status 
remain a challenge. Disclosure has been shown to confer the following benefits. 
The study sought to assess the knowledge of HIV status of adolescents and young 
adults. MethOds: A baseline study was conducted to ascertain if adolescents and 
young adults knew their HIV status and also determine their knowledge on HIV in 
general with 34 participants. An adolescent club was established to engage with 
young people, provide better tailored care and support and to solve their peculiar 
